The Armchair Analyst

The Armchair Analyst

5-minute daily updates on the ASX life-sciences sector.

Recent Articles

CAR-T Cell Therapies back on the menu with $7.8 billion acquisition

CAR-T Cell Therapies back on the menu with $7.8 billion acquisition

Feb 24, 2026

•

6 min read

Sprinting to the starting line: The Rhythm Biosciences (ASX: RHY) Story

Sprinting to the starting line: The Rhythm Biosciences (ASX: RHY) Story

Feb 23, 2026

•

13 min read

The Three-Day Market Update

The Three-Day Market Update

Feb 20, 2026

•

10 min read

The Price of Buying Time: The Adherium (ASX: ADR) Story

The Price of Buying Time: The Adherium (ASX: ADR) Story

Feb 17, 2026

•

12 min read

The Path to Blue-Chip: The Clarity Pharmaceuticals (ASX: CU6) Story

The Path to Blue-Chip: The Clarity Pharmaceuticals (ASX: CU6) Story

Feb 16, 2026

•

13 min read

Why do stocks fall on good news

Why do stocks fall on good news

Feb 13, 2026

•

10 min read

The Greatest Wealth Creator in Australian Biotech: The CSL Story

The Greatest Wealth Creator in Australian Biotech: The CSL Story

Feb 12, 2026

•

11 min read

Why I'm not catching the CSL falling knife

Why I'm not catching the CSL falling knife

Feb 11, 2026

•

8 min read

A 20-Year Overnight Success: The Memphasys (ASX: MEM) Story.

A 20-Year Overnight Success: The Memphasys (ASX: MEM) Story.

Feb 10, 2026

•

12 min read

Why fundamental analysis doesn't work for Biotech Stocks

Why fundamental analysis doesn't work for Biotech Stocks

Feb 9, 2026

•

8 min read

No Man's Land: Why Cheap Stocks Can Still Be Hard Trades

No Man's Land: Why Cheap Stocks Can Still Be Hard Trades

Feb 6, 2026

•

11 min read

How medtech survives the SaaSpocolypes

How medtech survives the SaaSpocolypes

Feb 5, 2026

•

9 min read